drugset
drugset / Trial / NCT04014257

A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies

NCT04014257 ↗

Phase 1 Completed 17 enrolled Handok Inc. CMG Pharmaceutical Co. Ltd · collab
NaSingle-groupOpen-labelTreatment

Summary

This study is a first-in-human (FIH) study which is required to understand the PK characteristics, MTD, and safety profile of NOV1601(CHC2014) in subjects with solid organ malignancies.

Timeline

Start
2019-08-09
Primary completion
2021-01-22
Completion
2021-01-29

Drugs

EvaluationDrugModalityDoseRoute
Subject BODITRECTINIB Small molecule — —

Indications

cancer